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Recombinant human erythropoietin treatment improves platelet func-
tion in uremic patients. The effect of recombinant human erythropoietin
(rHuEPO) on primary hemostasis was tested in 19 hemodialyzed
patients. Bleeding time, platelet aggregation and platelet interaction
with vessel subendothelium (SE) under flow conditions were deter-
mined before treatment and after patients reached hematocrits 30%.
Two thrombotic events (an acute myocardial infarction and an AV
fistula clotting) were recorded during the early stages of treatment. A
shortening of average bleeding times (P < 0.01), an increase in platelet
count (P < 0.01) and an improvement of platelet aggregation (P < 0.01)
and of platelet-SE interaction (P < 0.01) were observed. A low
correlation index was found between hematocrit and bleeding time (r =
—0.351, P < 0.05). To assess a possible effect of rHuEPO on platelet
function, the same parameters were evaluated before and after receiv-
ing three doses of rHuEPO (40 U/kg i.v. post-hemodialysis) in 14 of the
patients. No changes in platelet or erythrocyte counts were observed,
the mean bleeding time remained unchanged, but platelet aggregation
induced by arachidonic acid (P < 0.05), ADP (P < 0.01) and ristocetin
(P < 0.05) improved. Perfusion studies confirmed moderate but signif-
icant increases in the parameters that quantify platelet-SE interaction
(P < 0.05). Improvement of ADP-induced aggregation correlated with
the increase of platelet adhesion to SE (r = 0.675, P < 0.05). We
conclude that rHuEPO treatment improves primary hemostasis in
uremia through an increase of red cell mass but also through a beneficial
effect on platelet function, which is independent of the hematocrit rise.
Uremia is commonly associated with a bleeding tendency due
to an impaired interaction of platelets with vessel subendothe-
hum and a defective aggregate formation [1, 2], which is
reflected by a prolonged skin bleeding time [3].
The anemia, frequently present in chronic renal failure, has
been implicated in the pathogenesis of the hemostatic defect of
uremic patients. The prolonged bleeding time is related to the
severity of anemia and it has been demonstrated that red cell
transfusions improve clinical bleeding, shorten the prolonged
bleeding time and increase platelet adhesiveness to glass beads
in hemodialyzed patients [4, 51.
Recombinant human erythropoietin (rHuEPO) has been
proven to correct effectively the anemia of chronic renal failure
[6, 7]. A shortening in bleeding time and an improvement in
platelet adhesion to vessel subendothelium after rising the
Received for publication September 24, 1991
and in revised form March 30, 1992
Accepted for publication March 30, 1992
© 1992 by the International Society of Nephrology
hematocrit with rHuEPO have been reported [8, 9]. This
hemostatic effect has been related to the increase in red cell
mass and the resultant rise in blood viscosity [8]. However, an
increase in platelet count and an improvement in platelet
aggregability have also been reported during rHuEPO treatment
[9, 10]. Furthermore, a risk for thrombosis, such as AV fistula
clotting, has been claimed for uremic patients under rHuEPO
treatment [11—13].
The aim of this study was to analyze the effect of rHuEPO
treatment on primary hemostasis in uremic patients and to
elucidate whether this effect is related to the red cell mass
increase and/or to an effect of rHuEPO on platelet function. For
this purpose, bleeding time, platelet aggregation in platelet-rich
plasma and platelet/vessel wall interaction in a flowing system
were studied in uremic patients after they had achieved hema-
tocrits 30% and were in early stages of rHuEPO treatment.
Methods
Patients
Nineteen stable hemodialysis patients who were transfusion
dependent [13 men and 6 women, mean age 50 16 years (mean
SD, range 28 to 77 years)], mean time on dialysis 79 64
months (range 12 to 194 months) were included in the study
after giving informed consent. Causes of renal failure were:
Chronic glomerulonephritis (6 patients), polycystic kidney dis-
ease (3), nephroangiosclerosis (3), hemolytic uremic syndrome
(1), diabetic nephropathy (2), obstructive uropathy (1) and
unknown (2). Platelet counts and coagulation tests (prothrom-
bin time, partial thromboplastin time and fibrinogen levels)
were within the normal range in all patients. Patients were
dialyzed for four hours thrice weekly through a wrist or brachial
AV fistula. Cellulose acetate hollow fiber dialyzers (CA 150,
Nissho Corp. Osaka, Japan) and bicarbonate buffer dialysate
were used in all patients. No patient had received blood related
products at least one month before and all throughout the study,
and none had taken aspirin or other drugs known to affect
platelet function in the two weeks prior to the studies.
Patients received rHuEPO at an initial dose of 40 U/kg i.v.
three times weekly at the end of the dialysis session. This dose
was increased by 40 U/kg every four weeks until hematocrit
raised at least 3%, in order to achieve an hematocrit higher than
30%.
668
Cases et a!: EPO and platelet function in uremia 669
Study design
Protocol 1. Patients were examined before starting the treat-
ment and when they achieved a hematocrit equal or higher than
30%, since previous studies demonstrated that hematocrits of
about 30% were usually sufficient to correct the bleeding time
and to improve the bleeding tendency in uremic patients [4, 81.
Protocol 2. The possible effect of rHuEPO on platelet func-
tion could be fulfilled in a subset of 14 patients who were
examined before and after the third dose of rHuEPO (40 U/kg
i.v. after each dialysis session).
The studies were always performed before the hemodialysis
session. These included a complete blood cell count, skin
bleeding time, platelet aggregation in vitro induced by several
agonists, and platelet adhesion to vessel subendothelium in a
flowing system.
Laboratory tests
Full blood counts were performed on EDTA anticoagulated
blood (4 m final concentration) using an automatic electronic
counter (Technicon HlTM System, Technicon Instruments
Corp, Tarrytown, New York, USA). The bleeding time was
measured in the volar surface of the arm with an automated
template device (Simplate II; General Diagnostics, Morris
Plains, New Jersey, USA) [141. Bleeding time was considered
as "corrected" when it became shorter than or equal to seven
minutes, our upper normal limit for this test, and it was defined
as shortened when it shortened from baseline values by at least
20%. Values higher than 30 minutes were considered as 30
minutes. The coefficient of variation of this test is 20%. Blood
samples for aggregation and perfusion studies were collected in
ACD anticoagulant (sodium citrate 0.1 mol/liter, citric acid 7
mmollliter dextrose 0.14 mol/liter, pH 6.5; 9:1, vol:vol). Platelet
aggregation in platelet-rich plasma was performed by the Born's
method [15] using a lumiaggregometer Aggrecoder PA 3210
(DIC, Kyoto, Japan). The following agonists were used: ade-
nosin 5' diphosphate (ADP) 2 sM (Sigma Chemical Co., St.
Louis, Missouri, USA), arachidonic acid 1.4 mrvi (Menarini
Diagnostica, Milan, Italy), collagen 5 pg/ml (Menarini Diagnos-
tica), epinephrine 10 sM (Menarini Diagnostica) and ristocetin 1
mg/mI (Lundbeck & Co, Copenhagen, Denmark). The coeffi-
cient of variation intra-assay of this technique in our laboratory
is 8.3%.
Platelet interaction with vascular subendothelium was mea-
sured in a flowing system [16]. The anticoagulant was adjusted
to attain a final Ca2 concentration above 30 tM. Perfusions
were carried out at 37°C in perfusion chambers, developed by
Baumgartner, that had an effective annular width of 2.2 mm and
a rod length of 7.2 cm. Alpha-chymotrypsin denuded rabbit
aortas were inserted on plastic rods and exposed to flowing
blood. Flow obtained through a peristaltic pump was main-
tained at 140 ml/min (wall shear rate 800 sec'). This shear rate
is similar to those found in medium sized arteries or at sites of
AV shunts. After 10 minutes of perfusion, vessel segments were
rinsed with phosphate buffered saline, fixed for one hour in 3%
glutaraldehyde, dehydrated through graded series of ethanol,
embedded in JB-4 compound (Polysciences, Warrington, Penn-
sylvania, USA), thin sectioned for light microscopy and stained
with methylene blue. The coefficient of variation intra-assay of
this technique in our laboratory is 15.6%.
Interaction of platelets with vessel subendothelium was mor-
phometrically evaluated according to Baumgartner and Muggli
[171 by a technician who was unaware of the origin of the
samples evaluated and the aim of the study. A computerized
method was used for these evaluations [18]. Platelet or groups
of platelets were classified as follows: contact (C), platelets that
are attached but not spread on the subendothelium; adhesion
(A), platelets that are spread on subendothelium or forming
layers less than 5 sm in height; and thrombi (T), platelet
aggregates 5 m or more in height. All of these basic parameters
were expressed as a percentage of the total length of the vessel
screened. The total covered surface was obtained by adding the
previous basic parameters (C+A+T). For the sake of clarity, in
the present study we have referred to results on total covered
surface, a parameter that estimates the overall deposition of
platelets on vascular subendothelium and thrombi, an estima-
tion of platelet-to-platelet interaction.
Statistics
Results are expressed as mean SD. Student's t-test for
paired data was used for statistical comparisons. Correlation
coefficients were calculated by the least squares method. A
value of P < 0.05 was considered statistically significant.
Results
Protocol I
Patients achieved the expected hematocrit after 9.1 3.5
weeks of treatment (range 4 to 14 weeks) and after a mean dose
of rHuEPO of 65 23 lU/kg (range 40 to 120 lU/kg).
During treatment with rHuEPO one patient with previous
angina pectoris died from an acute myocardial infarction on the
sixth week of treatment and coinciding with an increase in the
rHuEPO dose. Another patient suffered a thrombosis of her
arteriovenous fistula after the third dose of rHuEPO. Seven of
the patients required an increase of the heparin doses during
dialysis to avoid clotting of the dialyzer; the mean requirements
of heparin rose significantly during rHuEPO treatment (from
4583 492 IU to 5139 1026 IU, P < 0.05).
The bleeding time, which was initially prolonged in all 19
patients, shortened in 11 out of the 18 patients who ended the
study, but correction was achieved in only four of them, while
the bleeding time remained unchanged in 7 patients. Mean
bleeding time also shortened significantly (from 20.5 8.8 mm
to 14.3 7.9, P <0.01; Fig. 1).
Platelet count increased significantly during the treatment
with rHuEPO (P < 0.01), but no changes in platelet volume
were observed (Table I). Platelet aggregation induced by ara-
chidonic acid (P < 0.01), ADP (P < 0.01), collagen (P < 0.01),
epinephrine (P < 0.01) and ristocetin (P < 0.01) improved
significantly (Table 1). Furthermore, the parameters that quan-
titate platelet-subendothelium interaction in perfusion experi-
ments in vitro also improved significantly after correcting
anemia with rHuEPO (Table 1).
Bleeding time showed a poor inverse correlation with hema-
tocrit (r =
—0.351, P < 0.05; Fig. 2). Platelet adhesion to
subendothelium showed no correlation with either hematocrit
or platelet count. No correlation was found between the dose of
rHuEPO and the shortening of bleeding time or the improve-
ment in platelet adhesion to subendothelium.
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Table 1. Changes of the different parameters evaluated before and






Hematocrit % 21.7 2.29 31.5 1.2k
Platelet count xJ/pJ 165.6 63 197.2 59
Platelet volume ft 8.52 1.1 8.73 0.9
Bleeding time miii 20.5 8.8 14.3 7•9a 37
Platelet aggregation in vitro %
Arachidonic acid (1.4 mM) 51.6 15 72.3 l6a 75—100
Adenosine diphosphate (2 .tM) 43.4 13 67.2 l8 65—100
Collagen (5 gIml) 57.8 12 71.8 l3 75—100
Epinephrine (10 jsM) 45.2 10 70.8 17 65—100
Ristocetin (1 mg/mI) 55.1 12 77.4 13 70—100
Platelet-subendothelium
interaction
Covered surface % 7.5 5.1 16.6 10.4k 25—42
Thrombi % 1.36 1.1 7.1 5.la 13—28
Data are mean SD.
a p < 0.01 with respect to baseline values
Protocol 2
After the third dose of rHuEPO there were no significant
changes in either values of hematocrit, platelet count, platelet
volume or bleeding time (Table 2). Platelet aggregation in vitro
induced by arachidonic acid (P < 0.05), ADP (P < 0.01) and
ristocetin (P < 0.05) improved significantly (Table 2). There
was also a moderate but significant improvement in the param-
eters that quantify platelet-subendothelium interaction in per-
fusion studies (P < 0.05; Table 2). The increase in the adhesion
of platelets to vessel subendothelium after rHuEPO correlated
with the improvement of ADP-induced platelet aggregation (r
0.675, P < 0.05; Fig. 3).
Discussion
In this study, the effects of rHuEPO treatment for correction
of renal anemia on primary hemostasis in uremic patients were
evaluated by means of three different tests: (1) skin bleeding
time, probably the best in vivo test that evaluates globally
primary hemostasis; (2) platelet aggregation in vitro, the stan-
Table 2. Changes of the different parameters evaluated bef




Hematocrit % 21.5 2.29 21.6 2.41
Platelet count x 103/j.d 161 63 166 58
Platelet volumeft 8.46 1.3 8.51 1.2
Bleeding time mm 20.1 9 19.1 10 3—7
Platelet aggregation in vitro %
Arachidonic acid (1.4 mM) 46.9 5 61.7 16 75—100
Adenosine diphosphate (2 sM) 41.4 14 53.9 10" 65—100
Collagen (5 g/m1) 53.3 10 55.4 10 75—100
Epinephrine (10 M) 46.1 7.6 48.7 11 65—100
Ristocetin (1 mg/mI) 48.1 17 60.3 14 70—100
Platelet-subendothelium
interaction
Covered surface % 5.67 2.7 8.63 5.6a 25—42
Thrombi % 1.44 1.16 3.79 3.19a 13—28
Data are mean SD.
a P < 0.05 and bP < 0.01 with respect to baseline values
dard procedure to assess platelet function; and (3) platelet-
subendothelium interaction, in which adhesive and cohesive
functions of platelets can be assessed under flowing conditions.
Our results suggest that rHuEPO treatment improves primary
hemostasis in uremic patients through the increase in red cell
mass and through an improvement of the impaired platelet
function, an effect which is independent of the hematocrit rise.
The results of the first protocol confirmed that correction of
anemia with rHuEPO shortens the bleeding time and improves
platelet-subendothelium interaction in hernodialyzed patients
[8—10, 19, 20], a phenomenon which has been previously
ascribed to the increase in circulating red cells and the resultant
increase in blood viscosity [8, 19, 20].
Red cells increase platelet adhesion in flowing blood by
promoting the radial diffusion of platelets towards the vessel
wall, thereby facilitating their adhesion to vessel subendothe-
hum [21]. In chronic renal failure patients the bleeding time is
















on bleeding time in uremic pa-
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t ig. 2. Correlation between bleeding time and hematocrit. Unfilled
dots before treatment and solid dots after treatment. y = —0.21 x +
30.3; r =
—0.351; P < 0.05.
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red cell transfusions [4, 5]. However, uremic patients have
longer bleeding times than non-uremic patients with a similar
degree of anemia [4], indicating that the pathogenesis of this
defect is multifactorial. Along with anemia, plasma [2, 22] and
platelet factors [2] have been implicated in the hemostatic
defect present in uremic patients. Several observations from
our study suggested that another effect, in addition to the
hematocrit rise, seemed to play a role in the beneficial effect of
rHuEPO treatment on primary hemostasis. Thrombotic events
were observed early in the treatment in our patients, before any
significant hematocrit rise was recorded, coinciding with obser-
vations from previous reports [13, 23]. Platelet aggregability in
platelet rich plasma improved significantly, which is in agree-
ment with some previous authors [9, 10], but not with others
[19, 20]. This effect cannot be ascribed to the hematocrit rise,
since red cell transfusions seemed not to affect platelet aggre-
gability in uremic patients [5]. The slight increase in platelet
number observed during rHuEPO therapy is also unlikely to
affect by itself the amplitude of aggregation, suggesting a
beneficial effect of rHuEPO on the impaired platelet function in
uremia. Furthermore, the low correlation observed between
hematocrit and bleeding time points to the presence of other
contributing mechanisms in the hemostatic effect of rHuEPO
treatment. In most patients the bleeding time remained pro-
longed despite correction of anemia, and platelet aggregability
improved but was not corrected, suggesting that the platelet
dysfunction of uremic patients is not completely reversed by
rHuEPO. Furthermore, this beneficial effect of rHuEPO on
platelet function has been reported to be transient [9].
In the second study, although we failed to find a shortening of
the bleeding time, a slight but significant improvement of
platelet interaction with subendothelium was observed early in
the treatment with rHuEPO, before any increase in red cell
mass or platelet count were recorded, indicating a beneficial
effect of this treatment on primary hemostasis, which was
independent of the hematocrit rise. The discrepancy of the
effects of rHuEPO treatment on bleeding time and platelet
adhesion to subendothelium may be due to the lower sensitivity
of the first test to detect changes on hemostasis. The parallel
improvement of platelet aggregability and the correlation ob-
served between the increase in platelet adhesion to vessel
subendothelium and the improvement of ADP-induced platelet
aggregation indicate that this early hemostatic effect is due to
the amelioration of the abnormal platelet function.
The improved platelet function does not seem to be caused by
a direct effect of rHuEPO on platelet function since in vitro
addition of rHuEPO to citrated uremic blood in a flowing
system did not improve platelet-subendothelium interaction
(data not shown). This is probably due to the release to the
blood of young platelets which are metabolically more active.
rHuEPO has been reported to stimulate certain aspects of
megakaryocyte maturation [24] and megakaryocyte colony for-
mation [25, 26]. The increase in platelet count and platelet
volume observed by several authors suggest that formation and
release of new platelets might be enhanced during rHuEPO
treatment. The fact that we were unable to demonstrate an
increase in mean platelet volume may be due to the anticoagu-
lant used in our experiment (EDTA); which has been reported
to induce platelet swelling [27]. Erythropoietin also seems to
increase platelet free-calcium mobilization, which is needed for
platelet aggregation in vivo [28].
Results obtained from our study suggest that rHuEPO may
have a proaggregant effect. Despite the limited number of
patients included in this study, two thrombotic events appeared
early during the course of treatment, in agreement with previ-
ous reports [13, 23]. In a placebo-controlled trial an increased
incidence of fistula thrombosis has been demonstrated in pa-
tients treated with rHuEPO [23]. Recently, rHuEPO has been
reported to increase in vitro whole-blood spontaneous platelet
aggregation in hemodialyzed patients and that concomitant
aspirin administration reversed platelet hyperaggregability [29].
Therefore, addition of antiplatelet drugs should be considered
in uremic patients treated with rHuEPO, especially if they are
at risk for thrombosis.
In conclusion, correction of anemia with rHuEPO improves
primary hemostasis in uremic patients. This effect is due to the
hemostatic effect of the increased red cell mass, as well as to a
partial improvement of the abnormal platelet function.
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